Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04855929
Other study ID # ANV419-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 25, 2021
Est. completion date January 2025

Study information

Verified date February 2024
Source Anaveon AG
Contact Claudia Schusterbauer, MD
Phone +41615218383
Email anv419-001clinicaltrial@anaveon.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.


Description:

The purpose of this First-in-Human, open-label, dose escalation study is to assess the initial safety and efficacy profile of ANV419 intravenous infusion alone and in combination with ipilimumab in patients with advanced solid tumours. It will evaluate the safety and tolerability of ANV419 alone and in combination with ipilimumab and, the safest and best dose of ANV419 when used alone or in combination.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date January 2025
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ability of the patient or legal guardian to understand the purpose of the study, provide signed and dated informed consent from the patient prior to performing any protocol-related procedures (including Screening evaluations), and be able and willing to comply with the study procedures. - Male or female aged = 18 years. - Advanced solid tumors with evidence of progressive disease as per RECIST no longer than 3 months before Informed Consent form (ICF) signature, without any subsequent curative intent treatment. - Parts A and B only: Histologically confirmed relapsed/refractory advanced solid tumor, progressing after at least one line of treatment for advanced or metastatic disease - Part C only: Previously treated advanced NSCLC without a driver mutation who have progressed after first line standard chemo-immunotherapy: Patients must have measurable disease using RECIST v1.1, A maximum of 1 line of therapy is permitted, Patients with high expression of PD-L1 which were treated with first line checkpoint inhibitor monotherapy may have received a maximum of 2 lines of therapy - Part D only: Histologically confirmed relapsed/refractory advanced solid tumors progressing after at least one line of treatment for advanced disease. Patients with NSCLC who do not meet inclusion criteria for Part C, are eligible for Part D - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. - Adequate pulmonary, cardiovascular, hematological, liver and renal function, per Investigator judgment. - All acute toxic effects, of any prior anticancer therapy (e.g., radiotherapy, chemotherapy, or surgical procedures) must have resolved to CTCAE v5.0 grade =1 (except alopecia [any grade] or fatigue [up to grade 2 allowed]). - Negative serum pregnancy test at screening and a negative (urine or serum) pregnancy test within 7 days prior to study day 1 in women of childbearing potential and women <12 months after menopause. - Women who are not postmenopausal and who have not undergone surgical sterilization: must agree to use highly effective methods of contraception during the treatment period and until 6 months after the last dose of study treatment. They must also agree to not donate eggs (ova, oocytes) during the same timeframe. - All men with childbearing potential partners must agree to use highly effective methods of contraception and barrier contraception (condom) during the treatment period and for 6 months after the last dose of study treatment. They must also agree to not donate sperm during the same timeframe. - Availability and willingness of patients to obtain a baseline and on treatment biopsy of the tumor. Available archived biopsies (frozen or formalin fixed) may serve as baseline specimens, in patients who have residual tumor masses which can only be accessed with significant risk Exclusion Criteria: - Carcinomatous meningitis and/or symptomatic central nervous system (CNS) metastases. Definitively treated CNS metastases (e.g., radiotherapy) stable for at least 6 weeks prior to Day 1 of study drug administration are acceptable. - Participants with an active second malignancy. Patients with precancerous lesions, concomitant early stages of prostate or breast cancer not requiring active treatment (past conditions currently resolved > 3 years prior to Screening are also acceptable), and squamous cell carcinoma of the skin not requiring systemic treatment are acceptable. - Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus, history of relevant pulmonary disorders, (e.g., severe bronchospasm, obstructive pulmonary disease), hyperthyroidism due to thyroiditis and known autoimmune diseases or other disease with ongoing fibrosis. Stable vitiligo, autoimmune thyroiditis, and preexisting treated type 1 diabetes are acceptable and are not exclusion criteria. - Significant cardiovascular/cerebrovascular disease, including myocardial infarction or transient ischemic attack (TIA) within 6 months prior to Day 1 of study drug administration. - Active infections, or uncontrolled infection requiring systemic antibiotics within one week (7 days) preceding Day 1 of treatment - Hemoglobin (Hb) <9 g/dL, transfusion of red blood cells allowed to reach threshold target. - Neutrophils <1500 /mm3. - Platelets <100'000/mm3. - Liver: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5xULN, if due to liver metastasis or primary liver cancer, AST or ALT >5x ULN. - Total bilirubin > upper limit of normal (ULN) (in documented Gilbert's syndrome, direct bilirubin > ULN). - International normalized ratio (INR) >1.5xULN. - Serum creatinine > ULN and estimated creatinine clearance < 50 mL/min using the Cockcroft-Gault formula. - Confirmed replicating human immunodeficiency virus (HIV) or confirmed active (replicative) hepatitis B virus or hepatitis C virus infection. Patients with treated non-replicative disease are acceptable. - Evidence of hepatic cirrhosis with Child-Pugh score C. - Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding > Grade 2 that give reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug. - Major surgery or significant traumatic injury <28 days prior to the first ANV419 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment. - Severe altered mental status. - Pregnant or breastfeeding women. - Known hypersensitivity to any of the components of ANV419 or its formulation. - Concurrent therapy with any other investigational drug within one month prior to Day 1 of study drug administration. - Active untreated immune-related endocrinopathies untreatable with replacement. Prior immune related toxicities > Grade 3 after treatment with immunostimulatory drugs (e.g., colitis, neuropathy) that have not completely resolved. - Chronic treatment with systemic immunosuppressive medications above 10 mg/day prednisolone equivalent for any reason. Additional exclusion criteria for Part D: - Experienced unacceptable drug-related toxicity with prior ipilimumab treatment (defined as toxicities that required second line immunosuppression, ie, not controlled by steroids alone) - Received ipilimumab within 6 months prior to cycle 1 day 1. - Known hypersensitivity to ipilimumab or any of its excipients - Patients with active autoimmune disease or a history of autoimmune disease (other than vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism), - Symptomatic interstitial lung disease - Concomitant use of therapeutic anti-coagulation (e.g.to treat pulmonary embolus or deep vein thrombosis). Prophylactic anti-coagulation is permitted.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ANV419
ANV419 administered by intravenous (IV) infusion
Ipilimumab
Ipilimumab administered by intravenous (IV) infusion

Locations

Country Name City State
Spain Hospital Vall d'Hebrón Barcelona
Spain START Madrid, Hospital Universitario HM Sanchinarro Madrid
Switzerland University Hospital Basel Basel
Switzerland Cantonal Hospital St.Gallen Saint-Gall
United Kingdom Royal Marsden Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Anaveon AG

Countries where clinical trial is conducted

Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Monotherapy: Number of Dose-Limiting Toxicities (DLTs) Day 1 to Day 14
Primary Combination: Number of Dose-Limiting Toxicities (DLTs) Day 1 to Day 21
Primary Monotherapy: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) Day 1 up to 12 months
Primary Combination: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) Day 1 up to 12 months
Primary Monotherapy: Recommended Phase 2 Dose Day 1 to Day 28
Primary Combination: Recommended Phase 2 Dose Day 1 to Day 28
Secondary Objective response rate (ORR) assessed by RECIST v1.1 for solid tumors Day 1 up to 12 months
Secondary Plasma concentration of ANV419 in blood Day 1 up to 12 months
Secondary Impact of ANV419 on the expression of markers of PBMC lineage in blood Day 1 up to 12 months
Secondary Levels of specific anti-ANV419 antibodies in blood Day 1 up to 12 months
Secondary Disease control according to RECIST v1.1 Day 1 up to 12 months
Secondary Progression-free survival (PFS) according to RECIST v1.1 Day 1 up to 12 months
Secondary Duration of response (DOR) according to RECIST v1.1 Day 1 up to 12 months
Secondary Overall survival (OS) Day 1 up to 12 months
Secondary Quality of life assessed with European Quality of Life Five Dimensions (EQ-5D-5L) Day 1 up to 12 months
Secondary Quality of life assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Day 1 up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Recruiting NCT05087251 - The Transitions Project: Efficacy Trial N/A